FDA's First "Bad Ad" Citation Goes To Hill Dermaceuticals
This article was originally published in The Pink Sheet Daily
Executive Summary
Program aimed at encouraging doctors to report promotions they find worrisome generates a DDMAC warning letter about a Web site for Derma-Smoothe.
You may also be interested in...
FDA Enforcement Letters On Rx Drug Promotions Plummet In 2013
OPDP Director Tom Abrams cautions against reading into the “snapshot.”
Hill Dermaceuticals Rewrites The Lab Books, So FDA Throws The Book At The Firm
A district court issued a consent decree against Hill, its president and quality assurance manager; government alleges the company repeatedly failed to correct violations cited by FDA since 2004.
Hill Dermaceuticals Rewrites The Lab Books, So FDA Throws The Book At The Firm
A district court issued a consent decree against Hill, its president and quality assurance manager; government alleges the company repeatedly failed to correct violations cited by FDA since 2004.